CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development

SHANGHAI, Aug. 27, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, announced appointment of Dr. Hong Ma as Senior Vice President, Clinical Development. Dr. Ma will be responsible for CARsgen clinical strategy, leading clinical development and medical team overseas.

"Dr. Ma's insights into clinical and medical affairs is a precious asset as CARsgen is implementing its global development," said Dr. Zonghai Li, Founder, CEO and CSO of CARsgen. "In the near future, CARsgen aims to submit several INDs overseas for our first-in-class and best-in-class CAR-T cell products. We are delighted to have Dr. Ma join, together with other internal and external professionals to deliver our commitment to cancer patients".

Dr. Ma is a seasoned medical oncologist with almost 20 years of cancer immunotherapy and orphan drug development experience, including over 15 years of pharmaceutical industry experience. Dr. Ma will build clinical development and medical affairs teams in US, enable CARsgen R&D program implementation and clinical research collaboration. He will lead medical and clinical development strategies and plans, which designated to the approval of CARsgen products overseas.

Dr. Ma has worked for leading companies of cancer immunotherapy. He served most recently as the Senior Medical Director & Senior Director of Clinical Development, Immatics Biotechnologies GmbH. Prior to this role, he was the Director, Clinical Development, Bellicum Pharmaceutical, Inc. Dr. Ma obtained his University Medical Degree (M.D.), M.Sc Oncology, in Hunan Medical University, (Now Xiangya Medical School, Central South University), Changsha, China and further acquired M.B.A degree from The University of Georgia, Athens, Georgia, US. Dr. Ma will be based in Houston, Texas.

About CARsgen Therapeutics
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of the first-in-class and best-in-class CAR-T therapeutics. The company has launched several First-in-Class CAR-T clinical trials to treat the relapsed/refractory tumors, including CAR-GPC3-T trial for hHepatocellular carcinoma and squamous lung cancer, CAR-EGFR/ EGFRvIII-T trial for GBM, and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs of the humanized CAR-CD19-T trial for leukemia and the fully human CAR-BCMA-T trial for multiple myeloma.

For more information, please visit www.carsgen.com

SOURCE CARsgen Therapeutics Co. Ltd.

Related Links

http://www.carsgen.com